All In Biotech

Drug Trial Radar · NCT05741294

A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

Open Phase IV Study to Assess the Impact of Tirbanibulin on the Wellbeing of Patients With Actinic Keratoses (TIRBASKIN)

Last checked: Nov 20, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

334

Actual

Start

Jan 20, 2023

Primary completion

Jan 19, 2024

Study completion Jan 19, 2024

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Feb 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5 consecutive days.

Conditions

  • Actinic Keratosis

Interventions

  • Tirbanibulin 2.5 mg ointmentDrug

    Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Total Score of Each Components at Day 57Time frame: At Day 57

Locations

37 sites in 2 countries. Site status is shown where the registry gives one.

  • Almirall Investigational Site 1

    Cagliari, Italy

  • Almirall Investigational Site 2

    Catania, Italy

  • Almirall Investigational Site 3

    Naples, Italy

  • Almirall Investigational Site 4

    Pisa, Italy

  • Almirall Investigational Site 5

    Rimini, Italy

  • Almirall Investigational Site 6

    Torino, Italy

  • Almirall Investigational Site 7

    Trieste, Italy

  • Almirall Investigational Site 1

    Alcorcón, Spain

  • Almirall Investigational Site 2

    Alicante, Spain

  • Almirall Investigational Site 3

    Badalona, Spain

  • Almirall Investigational Site 4

    Barcelona, Spain

  • Almirall Investigational Site 5

    Barcelona, Spain

  • Almirall Investigational Site 6

    Barcelona, Spain

  • Almirall Investigational Site 7

    Barcelona, Spain

  • Almirall Investigational Site 8

    Bilbao, Spain

  • Almirall Investigational Site 9

    Córdoba, Spain

  • Almirall Investigational Site 10

    Fuenlabrada, Spain

  • Almirall Investigational Site 11

    Granada, Spain

  • Almirall Investigational Site 12

    Madrid, Spain

  • Almirall Investigational Site 13

    Madrid, Spain

  • Almirall Investigational Site 14

    Madrid, Spain

  • Almirall Investigational Site 15

    Madrid, Spain

  • Almirall Investigational Site 16

    Majadahonda, Spain

  • Almirall Investigational Site 17

    Málaga, Spain

  • Almirall Investigational Site 18

    Palma, Spain

  • Almirall Investigational Site 19

    Pontevedra, Spain

  • Almirall Investigational Site 20

    Sabadell, Spain

  • Almirall Investigational Site 21

    Salamanca, Spain

  • Almirall Investigational Site 22

    Santa Cruz de Tenerife, Spain

  • Almirall Investigational Site 23

    Seville, Spain

  • Almirall Investigational Site 24

    Seville, Spain

  • Almirall Investigational Site 25

    Valencia, Spain

  • Almirall Investigational Site 26

    Valencia, Spain

  • Almirall Investigational Site 27

    Valencia, Spain

  • Almirall Investigational Site 28

    Vigo, Spain

  • Almirall Investigational Site 29

    Zaragoza, Spain

  • Almirall Investigational Site 30

    Zaragoza, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.